Health Catalyst (NASDAQ:HCAT) Raised to Overweight at KeyCorp

KeyCorp upgraded shares of Health Catalyst (NASDAQ:HCAT - Free Report) from a sector weight rating to an overweight rating in a research report released on Wednesday morning, MarketBeat.com reports. They currently have $9.00 target price on the stock.

A number of other brokerages have also commented on HCAT. Piper Sandler reiterated an "overweight" rating and issued a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Citigroup increased their target price on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Stephens lifted their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an "equal weight" rating in a report on Thursday, November 14th. Royal Bank of Canada increased their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a research note on Thursday, November 7th. Finally, Evercore ISI upped their target price on Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a report on Tuesday, October 8th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.50.

Health Catalyst Price Performance

Shares of HCAT traded up $0.38 during trading hours on Wednesday, reaching $7.36. 780,103 shares of the company traded hands, compared to its average volume of 560,940. The stock has a market capitalization of $447.84 million, a PE ratio of -5.45 and a beta of 1.36. The stock has a fifty day simple moving average of $7.83 and a 200 day simple moving average of $7.52. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to analysts' expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.22) EPS. As a group, research analysts predict that Health Catalyst will post -0.33 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Benjamin Landry sold 19,268 shares of the firm's stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the transaction, the general counsel now directly owns 72,250 shares in the company, valued at approximately $601,120. This trade represents a 21.05 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Jason Alger sold 19,599 shares of the business's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $163,063.68. Following the transaction, the chief financial officer now directly owns 86,712 shares of the company's stock, valued at approximately $721,443.84. This represents a 18.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 68,342 shares of company stock valued at $554,695 over the last quarter. Insiders own 2.50% of the company's stock.

Hedge Funds Weigh In On Health Catalyst

Large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. grew its holdings in shares of Health Catalyst by 6.9% during the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company's stock worth $188,000 after purchasing an additional 1,907 shares in the last quarter. Rhumbline Advisers boosted its stake in Health Catalyst by 9.1% during the second quarter. Rhumbline Advisers now owns 91,111 shares of the company's stock worth $582,000 after buying an additional 7,589 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in Health Catalyst by 276.3% in the 2nd quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company's stock valued at $1,365,000 after buying an additional 156,908 shares during the period. Acadian Asset Management LLC raised its stake in shares of Health Catalyst by 1.3% in the 2nd quarter. Acadian Asset Management LLC now owns 734,257 shares of the company's stock valued at $4,690,000 after buying an additional 9,697 shares in the last quarter. Finally, ClariVest Asset Management LLC lifted its holdings in shares of Health Catalyst by 1.2% during the 2nd quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company's stock worth $1,825,000 after acquiring an additional 3,302 shares during the period. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.